Blockage of CD300ld remodels the immune‐suppressive TME and shows anti‐tumour efficacy, as well as synergistic effects with immune checkpoint inhibitors, providing a promising target for cancer immunotherapy and other systemic inflammatory disorders where PMN‐MDSCs are implicated. This evidence concerns the gene CD300LD and neoplasm.